NCT01281813View on ClinicalTrials.gov

TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV

PHASE3CompletedINTERVENTIONAL

Enrollment

145

Participants

Timeline

Start Date

August 8, 2011

Primary Completion Date

July 29, 2021

Study Completion Date

July 29, 2021

Conditions

HIV-1 Infections

Interventions

DRUG

Darunavir

Participants will receive darunavir (per parent study) as oral suspension.

DRUG

Ritonavir

Participants will receive ritonavir (per parent study) as oral solution/suspension.

Trial Locations (17)

Unknown

Rio de Janeiro

San José

Guatemala City

Kuala Selangor

Panama City

Cape Town

Cyrildene Johannesburg Gauteng

Dundee

Durban

Johannesburg

Pretoria

Soweto

Westdene Johannesburg Gauteng

Bangkok

Chiang Mai

Khon Kaen

Vinnitsa

All Listed Sponsors

lead

Janssen Sciences Ireland UC

INDUSTRY

NCT01281813 - TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV | Biotech Hunter | Biotech Hunter